Getinge 2022 Annual Report slide image

Getinge 2022 Annual Report

Getinge 2022 Annual Report NOTE 33 Government grants Introduction Strategy Corporate Governance Annual Report Sustainability Report Other information Contents NOTE 34 Events after the end of the fiscal year During the year, Getinge received SEK 69 M (50) in government grants, of which SEK 2 M (5) was related to the outbreak of COVID-19. The COVID-19 related grants mainly concerned new employments, allowance for short-term work and compensation for sick leave costs from authorities in several different countries. Total government grants reported in the income statement amounted to SEK 55 M (28), of which SEK 50 M (30) was reported as other operating income and SEK 0 M (-6) as other operating expenses and SEK 6 M (4) reported as a reduction in the costs related to the grants. In addition to these, government grants have been received net of SEK 13 M (11) which reduced the carrying amount of the assets to which the grants were related. Except what is described below, no significant events have occurred after the end of the finacial year. The MDL process on product liability for surgical mesh in the US and Canada concluded with over 96% participation On January 30, 2023, Getinge's subsidiary Atrium Medical Corpora- tion concluded the settlement of the previously reported Multi- district Litigation (MDL) related to product liability for surgical mesh in the US and Canada. Getinge previously announced that Atrium Medical Corporation entered the settlement process on December 8, 2021. The settle- ment process and multidistrict litigation between Atrium Medical Corporation and the plaintiffs ended on January 30, 2023, with over 96% of eligible plaintiffs having opted into the settlement. The overwhelming majority of the settlement amount was paid as from January 30, 2023. The settlement is not an admission of liability or wrongdoing on the part of the company. Getinge and Atrium Medical Corporation will continue to defend themselves against any litigation not covered by this final settlement. The surgical mesh products were manufactured by Getinge's subsidiary Atrium Medical Corporation, which was acquired by Getinge in 2011. Since 2018, Getinge has made provisions of SEK 2.4 billion for expected costs related to surgical mesh claims, based on the information available at the time. The settlement payments were made as from January 30, 2023 and are covered by the provisions, and therefore do not affect the reported result for the period. Temporary suspended certificates for Getinge's HLS and PLS sets Getinge announced on February 23, 2023 that the notified body for certification services, DEKRA, has decided to temporarily suspend the CE-certificates for Getinge's HLS and PLS sets from March 1, 2023. Getinge is in dialogue with relevant authorities and working urgently to minimize the impact on patients. As previously commu- nicated, Getinge has identified and announced potential breaches in sterile packaging of the HLS and PLS sets used for extracorporeal respiratory and/or cardiovascular support. Getinge has since then reported progress to relevant authorities on a number of initiatives, such as package design improvements and advanced testing of the packaging to ensure that the products are protected by a sterile barrier according to the applicable standards and requirements. According to DEKRA the documentation related to the initiatives submitted from Getinge does currently not demonstrate compli- ance with the essential requirements according to the Medical Device Directive and applicable standards. As a result, DEKRA will temporarily suspend the CE-certificates for Getinge's HLS and PLS sets from March 1, 2023. Given the information Getinge has today, the financial impact is not expected to be material. Acquisition of Ultra Clean Systems Inc. After the end of the reporting period, Getinge completed acquisi- tion of 100% of the shares in Ultra Clean Systems Inc., a leading US manufacturer of ultrasonic cleaning technologies, used in hospitals and surgery centers to decontaminate surgical instruments. Ultra Clean Systems Inc. is located near Tampa, Florida, US, and gener- ated an annual revenue of SEK 90 M in 2022. The purchase price amounted to SEK 170 M (USD 16 M). The acquisition is not expected to have a material impact on Getinge's operating profit and earnings per share as of 2023. 113
View entire presentation